Lipid lowering effects

Lipid lowering effects represent a therapeutic outcome or pharmacological class rather than a specific molecular target such as a receptor or enzyme (StatPearls, 2023). This term describes the physiological reduction of circulating lipids, including low-density lipoprotein cholesterol (LDL-C) and triglycerides, which is a cornerstone in the management of cardiovascular disease and the prevention of atherosclerosis (NIH, 2024). These effects are achieved through the modulation of various distinct biological targets, most notably HMG-CoA reductase, which is inhibited by statins, and PCSK9, which is targeted by monoclonal antibodies or siRNA (PubMed, 2022). Because it encompasses a broad range of physiological changes mediated by different pathways, it is classified as a clinical endpoint or drug class effect rather than a single protein (FDA, 2023). Monitoring the efficacy of lipid-lowering interventions is standard clinical practice using serum lipid panels to assess risk reduction for major adverse cardiovascular events (AHA/ACC Guidelines, 2018).

Other names

Hypolipidemic effectAntihyperlipidemic effectLipid reductionCholesterol lowering

Lipid lowering is a therapeutic outcome achieved through various distinct mechanisms, including the inhibition of HMG-CoA reductase (statins), inhibition of the PCSK9 protein (monoclonal antibodies), activation of PPAR-alpha (fibrates), and inhibition of intestinal cholesterol absorption via NPC1L1 (ezetimibe) (StatPearls, 2023).